How Is AI Improving Drug Discovery for GLP-1 Analogues
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
The FDA has approved three GLP-1s in particular for both type 2 diabetes treatment and weight loss: Liraglutide (Saxenda, Victoza): While effective, this once-daily injection generally leads to more modest weight loss compared to newer options (its been around since 2014)
References Aminian A, Zajichek A, Arterburn DE, et al
Metabolism And Elimination In healthy individuals, the half-life of pramlintide is approximately 48 minutes
This maintains therapeutic levels in your blood and turns the process into a habit